XFOR
X4 Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.04
+0.00%Margins
Gross margin
81.2%
EBITDA margin
-501.8%
EBIT margin
-554.7%
Net margin
-568.8%
FCF margin
-528.4%
-58.0%
Return on equity
-35.6%
Return on assets
-37.8%
Return on invested capital
0.06x
Asset turnover
-$83.7M
Cash from operations
$2.10
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026